非炎症性前部缺血性视神经病变患者经复方樟柳碱治疗前后血浆内皮素1浓度的测定  

The Determination of Plasma Endothelin-1 Level in Nonarteritic Anterior Ischemic Optic Neuropathy Patients with Compound Anisodine before and after Treatment

作　　者：陈继远[1] 

机构地区：[1]重庆市第五人民医院,400062

出　　处：《中国医药指南》2009年第11期29-30,共2页Guide of China Medicine

摘　　要：目的测定非动脉炎性前部缺血性视神经病变(NAION)患者在复方樟柳碱治疗前后血浆中内皮素1(ET-1)的浓度,探讨其变化规律。方法NAION患者39例,给予复方樟柳碱2mL颞浅动脉旁注射,共治疗21d,所有患者按治疗效果分为三组(A组为治愈,B组为显效或有效,C组为无效),分别通过放射免疫法(RIA)测定治疗前后血浆ET-1浓度。结果各组治疗前的血浆ET-1浓度,A、B组高于C组,其差别有显著性意义(tAC=4.67,P<0.05;t.BC=4.03,P<0.05)),而A、B组之间差别无显著性意义(tA.B=1.34,P>0.1)。各组治疗后的血浆ET-1浓度,其分布规律同治疗前有统计学意义(tAC=4.13,P<0.05;tBC=3.89,P<0.05;tAB=0.67,P>0.1);各组治疗后的血浆ET-1浓度较治疗前均有所下降,A组、B组其治疗前后的浓度差别有显著性意义(FA=4.78,P<0.05;FB=4.32,P<0.05),C组治疗前后的浓度差别无显著性意义(FC=0.78,P>0.1)。结论复方樟柳碱对NAION患者的治疗效果,可能与血浆ET-1水平有关。Objective To measured the level of plasma endothelin-1 （ET-1）in patients with nonarteritic anterior ischemic optic neuropathy（NAION） before and after treatment by compound anisodine and to explore its changes rule. Methods 39 patients with NAION were treated by compound anisodine which was injected subcutaneously around superficial temporal artery once a day for 21days. All the patients were divided into three groups according to the results after treatment（groups A, CURE; group B, efficacy; group C, no efficacy）. The plasma levels of ET-1 in 39 cases before and after treatment were measured by radioimmuoassay（RIA）. Results The plasma levels of ET-1 before and after treatment in group A and group B were significantly higher than those in group C. There was no significantly difference between group A and group B.The plasma levels of ET-1 in patients after treatment were obviously lower than those before treatment. There was significantly difference in group A and group B but not in group C. Conclusion The efficiency of compound anisodine on patients with NAION may result in the plasma levels of ET-1.

关 键 词：缺血性视神经病变 复方樟柳碱 内皮素1 

分 类 号：R774.6[医药卫生—眼科]